Surrozen, Inc. Common SRZN
$33.68
+108.42%
at last close
Market Cap$189.94 million
P/E Ratio—
Div Yield—
Volume11.53M
52-Week Range
$10.73$35.86
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $42.00 (+24.7% upside)
Key Stats
- Today's Range
- $29.10 – $35.86
- 50-Day Range
- $16.14 – $35.86
- 52-Week Range
- $10.73 – $35.86
- Volume
- 11.53 million shs
- Average Volume
- 565K shs
- Market Cap
- $189.94 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -0.87
- Price / Sales
- 16.50
Short Interest
- Short Interest
- 0.33%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $11.51 million
- Net Income
- $-332,130,000
- Net Margin
- -2885.33%
- Return on Equity
- 151.89%
- Debt-to-Equity
- —
About Surrozen, Inc. Common
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
Related Stocks
Compare head-to-head: SRZN vs AMGN·SRZN vs MRNA·SRZN vs HALO·SRZN vs TWST
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.